Prognostic Value of Pre-Infarction Angina Combined with Mean Platelet Volume to Lymphocyte Count Ratio for No-Reflow and Short-Term Mortality in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Chen, Xinsen; Meng, Youbao; Shao, Mengle; Zhang, Tian; Han, Lina; Zhang, Wei; Zhang, Hongyan; Hai, Hua; Li, Guihua

doi:10.12659/msm.919300

Cited by 11 publications

(15 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study found that the level of MMP-9 in the culprit coronary artery in AMI patients was significantly higher in the no-reflow group than in the reflow group [57]. Kuliczkowski W. et al [58] also showed that patients with high MMP-9 levels are more likely to experience no-reflow, which is an independent factor in short-term mortality in patients with ACS [59]. There are also known studies proving the relationship between the occurrence of ventricular remodeling and a high level of MMP-9 in patients after ACS [60], which brings us to the potential benefit of determining the level of MMP-9 as a predictor of patient survival.…”

Section: Discussionmentioning

confidence: 96%

Matrix metallopeptidase 9 and outcome prediction in patients with acute coronary syndrome

Bilchenko

Vyshnevska

Hilova³

et al. 2022

Patologìâ

View full text Add to dashboard Cite

The aim of this review was to analyse the scientific literature data on matrix metallopeptidase 9 and to analyse the available information on its prognostic value as a marker of negative outcome in the short- and long-term prognosis in patients with acute coronary syndrome. Materials and methods. In our study was used a recursive literature search strategy at PubMed. The following criteria for inclusion in the analysis were defined – a prospective study in patients with acute coronary syndrome that had data on the effect of MMP-9 levels on short-term and/or long-term outcomes, including mortality and major adverse сardiovascular events. Review articles, clinical cases, animal studies, and studies with insignificant statistical data were not included in the analysis. The depth of the initial search was set at 15 years with a search for similar articles in citations. We selected 5 studies for meta-analysis. Meta-Essentials 1.5 was used for the analysis. Odds ratio and 95 % confidence interval were calculated using the Haenszel method. The association between MMP-9 levels and short-term and long-term outcomes (mortality and major adverse CV events) was determined. The statistically significant level was defined as P < 0.05. Results. The analysis showed no significant association between the level of MMP-9 and the outcome (OR = 1.39; 95 % CI = 0.25–7.79; P = 0.595; I2 = 78 %). Conclusions. Matrix metallopeptidase 9 is a promising marker for further investigation of its predictive strength of outcome. Despite the opposite results of single studies and no significant association of MMP-9 with outcome further research on this issue is a promising direction.

show abstract

Section: Discussionmentioning

confidence: 96%

Matrix metallopeptidase 9 and outcome prediction in patients with acute coronary syndrome

Bilchenko

Vyshnevska

Hilova³

et al. 2022

Patologìâ

View full text Add to dashboard Cite

show abstract

“…We found significant differences in white blood cell count, mean corpuscular volume, red cell distribution width, mean platelet volume, serum glucose, and bicarbonate levels between the survivors and the non-survivors. In different cohorts, these characteristics have been shown to be related to either short- or long-term mortality in STEMI [10,16–20]. The high performance of the IMRS in cardiogenic patients appears to be secondary to its contents; thus, this score has a significant value for use in high-risk patients.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of Intermountain Risk Score for short- and long-term mortality in patients with cardiogenic shock

İlker

Şaylık

Çağdaş

et al. 2023

Coronary Artery Disease

View full text Add to dashboard Cite

Background There is a lack of current research examining the predictive value of the Intermountain Risk Score (IMRS) in patients with ST-segment elevation myocardial infarction (STEMI) caused by cardiogenic shock. Therefore, the purpose of this research was to investigate the ability of IMRS to predict short- and long-term mortality in patients with cardiogenic shock triggered by STEMI. Methods The participants included 492 consecutive cardiogenic shock patients who underwent primary percutaneous coronary intervention following STEMI. The patients were separated into two groups depending on their survival status. The groups’ baseline characteristics, laboratory data, echocardiographic variables, and risk assessments were then compared. Next, the IMRS score was tested for its ability to predict both short- and long-term mortality. In order to assess its accuracy, the prognostic value of the IMRS was also compared that of the SYNTAX score II (SSII). Results After adjustment for the characteristics in the univariable study, multivariable Cox regression analysis indicated that the IMRS and SSII were both independently associated with short- and long-term mortality in STEMI patients with cardiogenic shock. However, the receiver operating characteristic curves indicated that the IMRS outperformed the SSII in terms of predicting both short- and long-term mortality. Conclusion This preliminary investigation showed that IMRS can predict both short- and long-term mortality in individuals with STEMI accompanied by cardiogenic shock.

show abstract

“…However, the current myocardial infarction (MI) risk scoring system is unable to detect the state of human inflammatory response. 2 …”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of the Leuko-Glycemic Index in Acute Myocardial Infarction Patients with or without Diabetes

Qi¹,

Liu²,

Cheng³

et al. 2022

DMSO

View full text Add to dashboard Cite

Prognostic Value of Pre-Infarction Angina Combined with Mean Platelet Volume to Lymphocyte Count Ratio for No-Reflow and Short-Term Mortality in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Cited by 11 publications

References 37 publications

Matrix metallopeptidase 9 and outcome prediction in patients with acute coronary syndrome

Matrix metallopeptidase 9 and outcome prediction in patients with acute coronary syndrome

Prognostic value of Intermountain Risk Score for short- and long-term mortality in patients with cardiogenic shock

Prognostic Value of the Leuko-Glycemic Index in Acute Myocardial Infarction Patients with or without Diabetes

Contact Info

Product

Resources

About